Bruder-Nascimento, T., Callera, G. E., Montezano, A. C., Belin de Chantemele, E. J., Tostes, R. C. and Touyz, R. M. (2019) Atorvastatin inhibits pro-inflammatory actions of aldosterone in vascular smooth muscle cells by reducing oxidative stress. Life Sciences, 221, pp. 29-34. (doi: 10.1016/j.lfs.2019.01.043) (PMID:30721707) (PMCID:PMC6686670)
|
Text
179337.pdf - Published Version Available under License Creative Commons Attribution. 888kB |
Abstract
Vascular inflammatory responses play an important role in several cardiovascular diseases. Of the many pro-inflammatory vasoactive factors implicated in this process, is aldosterone, an important mediator of vascular oxidative stress. Statins, such as atorvastatin, are cholesterol-lowering drugs that have pleiotropic actions, including anti-oxidant properties independently of their cholesterol-lowering effect. This study investigated whether atorvastatin prevents aldosterone-induced VSMC inflammation by reducing reactive oxygen species (ROS) production. Vascular smooth muscle cells (VSMC) from WKY rats were treated with 1 μM atorvastatin for 60 min or for 72 h prior to aldosterone (100 nM) stimulation. Atorvastatin inhibited Rac1/2 and p47phox translocation from the cytosol to the membrane, as well as reduced aldosterone-induced ROS production. Atorvastatin also attenuated aldosterone-induced vascular inflammation and macrophage adhesion to VSMC. Similarly EHT1864, a Rac1/2 inhibitor, and tiron, ROS scavenger, reduced macrophage adhesion. Through its inhibitory effects on Rac1/2 activation and ROS production, atorvastatin reduces vascular ROS generation and inhibits VSMC inflammation. Our data suggest that in conditions associated with aldosterone-induced vascular damage, statins may have vasoprotective effects by inhibiting oxidative stress and inflammation.
| Item Type: | Articles |
|---|---|
| Additional Information: | This work was supported by the São Paulo Research Foundation[grant numbers 2010/52214-6 (to R.C.T); 2011/01785-6; 2011/22035-5 (to T.B.-N.)]; Coordination for the Improvement of Higher EducationPersonnel (CAPES) [grant number: 88887.092495/2015-00 (to T.B.-N)]; the Agence Universitaire de la Francophonie [grant number58145FT103]; the Juvenile Diabetes Research Foundation [grantnumber4-2010-528]; the Canadian Institutes of Health Research [grantnumber 44018]; and the British Heart Foundation [grant number CH/12/429762]. |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Montezano, Dr Augusto and Touyz, Professor Rhian |
| Authors: | Bruder-Nascimento, T., Callera, G. E., Montezano, A. C., Belin de Chantemele, E. J., Tostes, R. C., and Touyz, R. M. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | Life Sciences |
| Publisher: | Elsevier |
| ISSN: | 0024-3205 |
| ISSN (Online): | 1879-0631 |
| Published Online: | 02 February 2019 |
| Copyright Holders: | Copyright © 2019 The Authors |
| First Published: | First published in Life Sciences 221: 29-34 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information